Biotechnology

From recommendation to reality: Why newborn screening n...

For the Sereno family, time has always been important. And for Lina Sereno, trus...

Argenx Expands Immunology Capabilities with Up-to-$1.15...

The deal is designed to marry UNP’s macrocyclic peptide discovery platform with ...

Automation a Path to Lower Cell Therapy Costs

Australian developer Currus Bio predicts that automating the production of its c...

Extracellular Vesicle Product Developer Creates Potency...

A company developing extracellular vesicle-based products has developed a potenc...

Hybrid Model Captures Lactate Run-Away and Back-Metabolism

A hybrid model provides hard-to-achieve insights into lactate performance during...

From Farm Waste to Medical Nanoparticles

Fruit peels, rice husks, and other crop leftovers can yield biomedical nanoparti...

How Breast Cancer Chemotherapy May Impact Biological Ag...

Chemotherapy helps many women survive breast cancer, but the results of new rese...

BioAdvance: BIO releases national action plan to streng...

A new seven-point plan to strengthen America’s biotechnology leadership amid int...

Illumina Offers Early Access to Duplex Sequencing for M...

Illumina has announced an early access program to a duplex sequencing workflow t...

How Cancer-Associated Gene Triggers Cell Division Witho...

A study showed how E2F1 can trigger cell division without having to unpack the c...

Cancer drug study puts numbers to the cost of IRA’s pil...

The price Americans pay for the Inflation Reduction Act (IRA) “pill penalty” and...

Formulation Development Roundup

What leaders suggest are the key considerations for developing robust formulatio...

Therapeutic Immune Manipulation

Next-generation immunotherapy exploits diverse immune populations to address the...

New AI Models Are Turbo-Charging Protein Design

Computer-designed protein therapeutics move from proof-of-concept to wet-lab val...

Childhood Cancers May Not Always Need Extra Mutations t...

Childhood cancers may not always need extra mutations to spread, a new review st...

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Imm...

Sanofi halted development of an oral STAT6 degrader that had been under study in...